MILFORD, Mass. - Aug 19, 2025 - Reprieve Cardiovascular, Inc., a clinical-stage medical device company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), announced the successful closing of an oversubscribed $61 million Series B financing round. The funding, led by Deerfield Management and supported by Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, Cadence Capital, and an undisclosed strategic investor, marks a significant milestone in advancing the company’s innovative Reprieve System. Concurrently, Reprieve has enrolled the first patient in its global FASTR II pivotal clinical trial, a critical step toward regulatory approval and commercialization.
The $61 million Series B financing comprises a combination of equity investment and a debt facility, designed to fuel Reprieve Cardiovascular’s growth. The round was led by Deerfield Management, a prominent healthcare investment firm, with participation from existing investors Arboretum Ventures, Lightstone Ventures, and Sante Ventures, alongside new investors Genesis Capital, Rex Health Ventures, Cadence Capital, and an undisclosed strategic partner. This diverse investor group brings both financial support and strategic expertise to accelerate Reprieve’s mission to transform heart failure treatment.
Strategic Goals and Use of Funds
The proceeds from the Series B financing will be allocated to key initiatives to advance Reprieve’s mission:
- Clinical Development:
- Primary Focus: Rapid execution of the FASTR II pivotal clinical trial to evaluate the efficacy and safety of the Reprieve System compared to optimal diuretic therapy in ADHF patients.
- Objective: Generate clinical evidence to support regulatory approval in key markets, including the U.S. and Europe.
- Commercial Readiness:
- Market Preparation: Development of commercial infrastructure, including manufacturing scale-up and market access strategies.
- Partnerships: Establishing strategic collaborations with healthcare providers and systems to facilitate adoption.
- Technology Enhancement:
- Product Optimization: Further refinement of the Reprieve System to enhance user experience and integration into clinical workflows.
- Research Expansion: Exploration of additional applications for the Reprieve System in heart failure management.
Historical Funding and Growth
Reprieve Cardiovascular has demonstrated steady progress in securing funding and advancing its clinical and operational milestones. The table below outlines the company’s funding history:
| Round | Date | Amount ($M) | Lead Investors | Key Milestones |
|---|---|---|---|---|
| Seed | Unknown | Undisclosed | Not specified | Initial development of the Reprieve System and early preclinical studies. |
| Series A | Unknown | Undisclosed | Not specified | Completion of early feasibility studies and initiation of the FASTR pilot study. |
| Series B | August 2025 | 61 | Deerfield Management | Enrollment of first patient in FASTR II pivotal trial; commercial readiness prep. |
The successful completion of the FASTR randomized pilot study in late 2024, which met both primary efficacy and safety endpoints, paved the way for the FASTR II pivotal study, underscoring Reprieve’s ability to attract significant investment.
Reprieve Cardiovascular’s Technology
The Reprieve System is a groundbreaking medical device designed to personalize decongestion management for patients with ADHF. Key features include:
- Real-Time Physiological Monitoring: Continuously tracks patient metrics to optimize fluid and sodium removal.
- Automated Therapy Recommendations: Uses intelligent algorithms to adjust diuretic dosing and saline replenishment, ensuring optimal kidney function.
- Seamless Clinical Integration: Designed to fit existing hospital workflows, reducing clinician workload while improving patient outcomes.
By addressing the challenges of fluid overload in heart failure, the Reprieve System aims to reduce hospital readmissions and enhance patient quality of life.
Industry Impact and Challenges
Heart failure affects over 25 million patients globally, with ADHF leading to frequent hospitalizations and high healthcare costs. Current diuretic-based treatments often lack precision, resulting in suboptimal outcomes and rehospitalizations. The Reprieve System addresses these challenges by offering a data-driven, personalized approach to fluid management. However, challenges remain, including navigating complex regulatory pathways and ensuring broad adoption in diverse healthcare systems. Reprieve’s focus on clinical evidence and strategic partnerships aims to overcome these hurdles.
Market Context and Industry Trends
The cardiovascular medical device sector is experiencing robust venture capital interest, with $539.4 million invested in cardiovascular technologies in Q2 2024, according to Pitchbook. This trend reflects growing recognition of the need for innovative solutions to address heart failure, the leading cause of death in the U.S. Despite this, cardiovascular research remains underfunded compared to oncology, with only 1-2% of NIH funds allocated to cardiovascular diseases annually. Reprieve’s success in securing significant funding highlights its potential to lead in this critical yet underinvested space.
Stakeholder Perspectives
- Mark Pacyna, CEO of Reprieve Cardiovascular: “This capital ensures we are positioned to generate the clinical and economic evidence essential for regulatory approval and commercialization. We believe our personalized approach to decongestion management can enable better outcomes for both patients and healthcare systems around the world.”
- David Neustaedter, Ph.D., Venture Partner at Deerfield Management: “We continue to be encouraged by the company’s clinical data and look forward to supporting their progress through this critical next stage of clinical and commercial development.”
- Anita Watkins, Managing Director, Rex Health Ventures: “Reprieve Cardiovascular is addressing a significant unmet need in today’s heart failure management paradigm, and the results from the FASTR pilot study underscore the potential of the Reprieve System to reimagine the standard of care for treating ADHF.”
Stakeholder Insights
The involvement of strategic investors like Rex Health Ventures and an undisclosed multinational partner signals confidence in Reprieve’s technology and market potential. Deerfield Management’s leadership in the round, combined with the diverse expertise of Arboretum, Lightstone, and Sante Ventures, positions Reprieve to leverage both financial and operational support. These partnerships are expected to facilitate clinical trial execution and pave the way for global commercialization.
About Reprieve Cardiovascular, Inc.
Reprieve Cardiovascular, Inc., headquartered in Milford, Massachusetts, is a privately held medical device company focused on improving outcomes for the more than 25 million patients worldwide with heart failure. The company’s proprietary Reprieve System delivers intelligent, personalized decongestion therapy for ADHF, aiming to enhance patient outcomes and reduce healthcare costs.
Future Outlook
With the FASTR II pivotal trial underway, Reprieve Cardiovascular is poised to generate critical data to support FDA and international regulatory approvals. The company aims to establish the Reprieve System as the standard of care for ADHF management, with potential expansion into other heart failure applications. Strategic partnerships and ongoing investor support will be key to scaling commercial operations and addressing the global heart failure burden.
Media Contact
Reprieve Cardiovascular, Inc.
Email: info@reprievecardiovascular.com
Website: www.reprievecardiovascular.com
